Our Pricing

Mounjaro NHS Eligibility & Access Information

Published on: June 03, 2026

Understanding mounjaro nhs eligibility uk criteria can be complex, especially with current supply constraints and strict prescribing guidelines. While Mounjaro (tirzepatide) is licensed by the MHRA for weight management in the UK, NHS access remains limited to specific patient groups through specialist services. At Cured Pharmacy, our UK-registered clinical team can assess your suitability for private prescription when NHS pathways aren't available or involve extended waiting times.

Current Mounjaro NHS Eligibility Criteria in the UK

NICE guidance currently restricts NHS-funded Mounjaro to adults with a BMI of 35 kg/m² or above (or 32.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds) who have at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. Patients must also have participated in a specialist weight management programme for at least 12 months without achieving adequate weight loss.

Even when eligibility criteria are met, access depends on local Integrated Care Board (ICB) funding decisions and specialist service capacity. Many NHS trusts have paused new referrals due to national supply constraints, creating waiting lists that can extend beyond 12 months in some regions [2]. Your GP cannot prescribe Mounjaro directly on the NHS — referral to a specialist tier 3 or tier 4 weight management service is mandatory under current commissioning arrangements.

The NHS typically prioritises patients with the highest clinical need, including those with BMI above 40 kg/m² or significant metabolic complications. If you fall outside these strict parameters or face prolonged waiting times, private prescription through a registered UK pharmacy offers an alternative route to access, subject to clinical assessment by a UK prescriber.

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK [1]. This dual mechanism distinguishes it from single-pathway treatments like semaglutide (Wegovy) or liraglutide (Saxenda), producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

In the landmark SURPASS-3 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks — significantly greater than the 14.9% seen with semaglutide 1mg in head-to-head comparisons [1][3]. The medication works by slowing gastric emptying, reducing appetite signals in the hypothalamus, and improving pancreatic beta-cell function, creating multiple pathways for sustainable weight management.

Clinical data demonstrates that approximately 91% of participants on the highest Mounjaro dose achieved at least 5% body weight reduction, with 57% reaching 20% or greater weight loss in clinical trials [1]. These outcomes were accompanied by improvements in cardiovascular risk markers including blood pressure, lipid profiles, and glycaemic control in patients with type 2 diabetes.

Weekly Injection Schedule and Dose Escalation

Mounjaro is administered once weekly via a pre-filled KwikPen injector, typically into the abdomen, thigh, or upper arm. Treatment begins at 2.5mg weekly for four weeks to minimise gastrointestinal side effects, then increases to 5mg for at least four weeks. Your UK prescriber may continue escalating the dose in 2.5mg increments every four weeks, up to a maximum of 15mg weekly, based on your tolerance and weight loss response. This gradual titration approach reduces the incidence of nausea and vomiting compared to rapid dose increases [1].

Private Mounjaro Prescription: When NHS Access Isn't Available

Private prescription through a UK-registered pharmacy like Cured Pharmacy offers an alternative for patients who don't meet strict NHS eligibility criteria, face extended waiting lists, or prefer to begin treatment without specialist service referral delays. Our clinical team assesses suitability based on your medical history, current medications, and weight management goals during a free online consultation that takes under three minutes to complete.

At Cured Pharmacy, Mounjaro is available from £124.99 for UK patients who meet private prescription criteria, which are generally broader than NHS thresholds but still require clinical justification. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing to ensure compliance with MHRA regulations and GPhC standards. Every prescription medication requires assessment by a UK-registered prescriber before dispensing — we never supply prescription-only medicines without proper clinical oversight.

Private treatment includes ongoing support from our UK clinical team, with regular follow-up assessments to monitor progress, adjust dosing, and manage any side effects. Patients receive genuine UK-licensed Mounjaro KwikPens in discreet packaging, with transparent upfront pricing shown before your consultation begins. There are no hidden fees or subscription lock-ins — you maintain full control over your treatment journey.

Who Can Access Private Mounjaro Prescriptions

Private prescription criteria typically require a BMI of 30 kg/m² or above (or 27 kg/m² with weight-related health conditions), though your prescriber will assess individual circumstances including previous weight loss attempts, contraindications, and treatment goals. Mounjaro is not suitable for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Pregnant or breastfeeding women cannot use tirzepatide due to insufficient safety data [4].

Mounjaro vs Wegovy: Comparing GLP-1 Weight Loss Treatments

Both Mounjaro and Wegovy are injectable treatments licensed by the MHRA for chronic weight management in the UK, but they differ in mechanism, efficacy data, and cost. Wegovy contains semaglutide, a GLP-1 receptor agonist that works through a single pathway, while Mounjaro's tirzepatide activates both GIP and GLP-1 receptors for potentially greater weight loss outcomes [3].

Head-to-head trial data suggests Mounjaro produces superior average weight reduction compared to semaglutide — 22.5% versus 14.9% at the highest doses over 72 weeks — though individual responses vary based on adherence, lifestyle factors, and metabolic characteristics [3]. Wegovy is available at Cured Pharmacy from £135.00 and may be more suitable for patients seeking a well-established GLP-1 treatment with extensive real-world safety data spanning several years of clinical use.

Both medications share similar side effect profiles, predominantly gastrointestinal symptoms including nausea, diarrhoea, and constipation that typically diminish after the initial dose escalation period. Your UK prescriber will consider your medical history, previous treatment responses, budget, and personal preferences when recommending the most appropriate option for your circumstances.

Managing Side Effects and Treatment Expectations

The most commonly reported side effects with Mounjaro are gastrointestinal in nature, affecting approximately 20-30% of patients during the initial dose escalation phase [1]. Nausea, reduced appetite, diarrhoea, and occasional vomiting typically peak during the first 4-8 weeks of treatment and resolve as your body adapts to the medication. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise these effects.

Rare but serious adverse events include pancreatitis (inflammation of the pancreas), gallbladder disease, and hypoglycaemia when used alongside other glucose-lowering medications. Patients should seek immediate medical attention if they experience severe abdominal pain, persistent vomiting, or signs of allergic reaction [4]. Our UK clinical team provides detailed guidance on recognising warning signs and managing common side effects throughout your treatment journey.

Realistic expectations are essential for successful outcomes. Clinical trials demonstrate that maximum weight loss typically occurs between 60-72 weeks of continuous treatment, with most patients experiencing gradual, sustained reduction rather than rapid drops [1]. Mounjaro works best when combined with dietary modifications and increased physical activity — medication alone cannot replace lifestyle interventions for long-term weight management success.

When to Contact Your Prescriber

Contact your UK prescriber if you experience persistent vomiting lasting more than 24 hours, severe abdominal pain, signs of pancreatitis, changes in vision, or symptoms of thyroid tumours such as a lump in the neck or persistent hoarseness. You should also report inadequate weight loss response after 16 weeks at the maintenance dose, as your treatment plan may need adjustment. Our clinical team at Cured Pharmacy remains available for ongoing support throughout your treatment course.

How to Start Your Mounjaro Assessment at Cured Pharmacy

Beginning your Mounjaro journey at Cured Pharmacy takes under three minutes through our secure online consultation platform. You'll complete a clinical questionnaire covering your medical history, current medications, weight management goals, and any contraindications that might affect suitability. A UK-registered prescriber reviews your assessment, typically within 24 hours, and approves your prescription if clinically appropriate.

Once approved, your Mounjaro KwikPen is dispensed by our GPhC-registered pharmacy team and dispatched in 100% discreet packaging with tracked delivery. We supply only genuine UK-licensed medications sourced through authorised wholesalers — never grey market or imported products. Pricing is transparent and shown upfront before your consultation begins, with no hidden fees or mandatory subscriptions.

Ongoing treatment includes regular follow-up assessments to monitor progress, adjust dosing, and ensure continued safety. You can pause or discontinue treatment at any time without penalty. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team remain available to answer questions, provide guidance on injection technique, and support you throughout your weight management journey. To begin your free assessment, visit our weight loss consultation page or contact our UK-based team on (+44) 116 4646009.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating overweight and obesity [TA1026]. NICE. https://www.nice.org.uk/guidance/ta1026 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics. Medicines.org.uk. https://www.medicines.org.uk/emc/product/14881 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is not suitable for everyone and may cause side effects. Individual results vary and are not guaranteed.